The optimal time for starting G-CSF application after
/l), similar criteria for starting G-CSF are surprisdays; time to platelet recovery, more than 50 × 10 9 /l: 24 ingly lacking. Additionally, in some patients conditioned days in both groups), use of blood products or antiwith protocols only slowly inducing neutropenia (eg with biotics, infections, or days of hospitalization. Delayed Gnon-Hodgkin's lymphomas (NHL) or Hodgkin's disease CSF application led to significant cost saving in terms (HD) conditioned with BEAM, multiple myeloma (MM) of APSCT (approximately US$1341 for each patient).
patients after high-dose melphalan: HD-L-PAM or after We suggest that 'patient-dependent' criteria for starting busulphan 16 mg/kg and cyclophosphamide 120 mg/kg G-CSF are reasonable especially in patients conditioned (BUCY2)) 'immediate' initiation of G-CSF therapy can with protocols only slowly inducing neutropenia: eg lead to leukocytosis as the blood picture at this time could NHL and HD patients after BEAM, MM after L-PAM be near to the norm. With regard to this fact and also taking or patients after busulphan and cyclophosphamide into account the patients' individual conditions the authors (BUCY2).
designed a randomized clinical trial comparing 'fixed' Keywords: autologous peripheral stem cell transplantation (APSCT); cost-effectiveness; granulocyte colonyadministration of G-CSF (day +1) vs delayed, 'patientstimulating factor (G-CSF); hematopoietic reconstitution dependent', (first day when ANC was below 0.5 × 10 9 /l) prophylactic therapy with G-CSF. 
Materials and methods

Statistical analysis
The data are given as the median and range. The differences Patients between the values were evaluated for statistical significance by two-tailed Student's t-test. Between June 1994 and January 1996, 70 patients with NHL, HD and MM were enrolled in the study (their detailed characteristics are shown in Table 1 ). The patients Results were randomized into two groups. Group A (n = 35) started G-CSF on day +1 after APSCT while patients in group B There were no differences found between the patients con-(n = 35) began G-CSF application when the ANC dropped ditioned with L-PAM and those receiving BEAM. below 0.5 × 10 9 /l. Both groups were comparable for median Detailed results are shown in Table 2 . age, sex distribution and disease stage, as well as previous therapies.
The number of CD34 + cells as well as nucleated cells Beginning of G-CSF application were similar in both groups: 3.7 × 10 6 /kg (1.24-9.62) G-CSF application in group A started on day +1 post-CD34 + cells in group A were infused vs 3.9 × 10 6 /kg (1.17-APSCT. In group B (where G-CSF application was started 10.5) in group B and 4.5 × 10 8 /kg (0.97-9.7) nucleated cells when the ANC was below 0.5 × 10 9 /l) G-CSF was started vs 4.9 × 10 8 /kg (0.83-8.3).
on day +4 post-transplant (+2 -+5).
Transplant protocol and G-CSF application Hematopoietic recovery
The pretransplant conditioning regimen (BEAM) for NHL The median times to reach an ANC of more than 0.5 × 10 9 /l and HD patients consisted of BCNU (300 mg/m 2 ), VP-16 were not significantly different between both groups (12 vs (800 mg/m 2 ), cytosine-arabinoside (1600 mg/m 2 ) and mel-13 days). There were also no detectable differences phalan-L-PAM (140 mg/m 2 ). MM patients received Lbetween the two groups in platelet reconstitution (the PAM 200 mg/m 2 . median time to reach more than 50 × 10 9 /l platelets): 24 Non-glycosylated recombinant human methionyl G-CSF days in both groups. (filgrastim; Neupogen, Hoffmann-La Roche, Basel, Switzerland) was administered as a continuous infusion at
Blood products a dose of 10 g/kg/day. G-CSF therapy was discontinued when ANC exceeded 1 × 10 9 /l for 3 consecutive days.
There were no differences in the red cell transfusions (three packed red cell units in both groups) or in platelet substitution (six single donor platelet transfusion units in both Supportive care groups).
The patients were hospitalized in single rooms with or without air filtration (HEPA). An indwelling central venous Infection, antibiotics, and days of hospitalization catheter was inserted in all cases. All patients received a There were no statistically significant differences between standard prophylactic oral antibiotic and antifungal therapy the two groups in the duration of therapy with broad-spec-(norfloxacine and fluconazole). Patients developing fever over 38°C during the neutropenic period were treated with in group A (15 days). This delay results in significant cost cytosis. The 'delayed' application of G-CSF offers a sigTransplant 1996; 17 (Suppl. 1): S42 (Abstr. 212). 14 Cetkovský P, Koza V, Š kopek P et al. Individual criteria nificant saving of cost without any negative impact on the rather than 'fixed' days could be optimal for starting of Grapidity of the engraftment. Hence, we conclude that indi-CSF administration after autologous peripheral stem cell transvidual criteria could be useful. actually need a post-transplant application of G-CSF.
